apiary 发表于 2025-3-23 12:55:59

http://reply.papertrans.cn/47/4622/462147/462147_11.png

变化 发表于 2025-3-23 14:29:46

http://reply.papertrans.cn/47/4622/462147/462147_12.png

dilute 发表于 2025-3-23 19:21:09

an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity. .978-1-4419-2608-1978-0-387-75841-1

不给啤 发表于 2025-3-23 23:33:30

http://reply.papertrans.cn/47/4622/462147/462147_14.png

PANEL 发表于 2025-3-24 04:33:57

http://reply.papertrans.cn/47/4622/462147/462147_15.png

辩论的终结 发表于 2025-3-24 09:13:26

Case Study: Immunogenicity of Interferon-Beta,quired for optimal and individualized therapies, and Ab detection induced during therapy. In an effort to assess the clinical relevance of in vitro Ab measurements, many investigators distinguish between ‘binding’ Abs (BAbs) and in vitro ‘neutralizing’ Abs (NAbs) even though such a distinction may n

Infusion 发表于 2025-3-24 13:15:37

http://reply.papertrans.cn/47/4622/462147/462147_17.png

仔细阅读 发表于 2025-3-24 18:02:49

,Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview,

情爱 发表于 2025-3-24 19:27:18

http://reply.papertrans.cn/47/4622/462147/462147_19.png

colloquial 发表于 2025-3-25 01:52:38

Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars,
页: 1 [2] 3 4 5 6
查看完整版本: Titlebook: Immunogenicity of Biopharmaceuticals; Marco van de Weert,Eva Horn Møller Book 2008 Springer-Verlag New York 2008 Biosimilar.drug.interfero